55. 再発性多発軟骨炎 Relapsing polychondritis Clinical trials / Disease details


臨床試験数 : 7 薬物数 : 10 - (DrugBank : 9) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 100

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003964-30-GB
(EUCTR)
22/10/202031/07/2020Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children.Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS) Non-ANCA associated vasculitides: 1.Giant cell arteritis (GCA)2.Takayasu’s arteritis (TA)3.Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN)4.Relapsing polychondritis (RP)5.IgA vasculitis (IgAV)6.Cogan’s syndrome7.Non-infective cryoglobulinaemia8.Primary angiitis of central nervous system (PACNS)
MedDRA version: 21.1;Level: PT;Classification code 10047115;Term: Vasculitis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Infliximab
Product Code: N/A
INN or Proposed INN: Infliximab
Trade Name: Rituximab
Product Name: Rituximab
INN or Proposed INN: Rituximab
Trade Name: Tocilizumab
Product Name: Tocilizumab
Product Code: N/A
INN or Proposed INN: Tocilizumab
Cambridge University Hospitals NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Phase 2United Kingdom
2NCT04077736
(ClinicalTrials.gov)
September 10, 20191/9/2019Low-dose Recombinant Human IL-2 for the Treatment of Relapsing PolychondritisA Pilot Study of Low Dose IL-2 in the Treatment of Relapsing PolychondritisRelapsing PolychondritisDrug: Interleukin-2Peking University People's HospitalNULLNot yet recruiting18 Years70 YearsAll10Phase 2NULL
3JPRN-UMIN000006950
2011/12/0126/12/2011Effects of additional inhaled tiotropium in relapsing polychondritis with airway involvement Relapsing polychondritisTo record subjective symptoms, pulmonary function, airway diameter and dimension 3 months before, at baseline and 3 months following tiotropiumSt. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal MedicineNULLComplete: follow-up completeNot applicableNot applicableMale and Female20Not selectedJapan
4NCT01272856
(ClinicalTrials.gov)
January 20116/1/2011Study on the Safety of Abatacept in Relapsing PolychondritisAn Open-Label, Single-Center, Phase I Study on the Safety of Abatacept in Relapsing PolychondritisRelapsing PolychondritisDrug: AbataceptBenaroya Research InstituteBristol-Myers SquibbCompleted18 Years80 YearsBoth4Phase 1United States
5JPRN-UMIN000003869
2010/07/0105/07/2010A clinical study to establish in diagnostic criteria and treatment guideline of relapsing polychondritis. Relapsing polychondritiscorticosteroid+methotrexate
corticosteroid+ciclosporin
St. Marianna University School of MedicineNULLRecruiting20years-oldNot applicableMale and Female30Not selectedJapan
6NCT01104480
(ClinicalTrials.gov)
May 201013/4/2010Tocilizumab for Relapsing PolychondritisEfficacy of Tocilizumab in a Patient With Relapsing PolychondritisRelapsing PolychondritisDrug: TocilizumabMcMaster Children's HospitalNULLWithdrawn12 Years15 YearsMale0Phase 2Canada
7NCT01041248
(ClinicalTrials.gov)
January 201030/12/2009Single Patient Study to Treat Relapsing Polychondritis With TocilizumabEfficacy of Tocilizumab in a Patient With Relapsing PolychondritisRelapsing PolychondritisDrug: TocilizumabChildren's Hospital of Eastern OntarioNULLCompletedN/AN/AMale1N/ACanada